The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

References

• McCullough PA, Beaver TM, Bennett-Guerrero E, et al. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med. 2014;15(1):11–23.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Legrand M, Kosiborod M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharmacol Res. 2016;113:585–591.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis: core curriculum. Am J Kidney Ds. 2019;74(5):682–695.
   PubMed Web of Science ®Google Scholar
• Dépret F, Peacock WF, Liu KD, et al. Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019;9(1):32.
   PubMed Web of Science ®Google Scholar
• Truhlář A, Deakin CD, Soar J, et al. European resuscitation council guidelines for resuscitation. Resuscitation. 2015;95:148–201.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2019;4:180–188.
   Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776–803.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl. 2013:1–150.
   Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. .
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur Heart J. 2018;33:3021–3204.
   Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Delpón E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32(1):99–119.
   PubMed Web of Science ®Google Scholar
• McDonough AA, Youn JH. Potassium Homeostasis: the Knowns, the Unknowns, and the Health Benefits. Physiology (Bethesda). 2017;32(2):100–111.
   PubMed Web of Science ®Google Scholar
• Welling PA, Welling PA. Roles and Regulation of Renal K Channels. Annu Rev Physiol. 2016;78(1):415–435.
   PubMedGoogle Scholar
• Kovesdy CP, Matsushita K, Sang Y, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;9(17):1535–1542. .
   Google Scholar
• Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–1162. .
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Delpón E. New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors – hype or hope? Discov Med. 2014 Nov;18(100):249–254.
   PubMed Web of Science ®Google Scholar
• Rajendran VM, Sandle GI. Colonic potassium absorption and secretion in health and disease. Compr Physiol. 2018;8:1513–1536.
   PubMed Web of Science ®Google Scholar
• An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16(6):R225. .
   PubMed Web of Science ®Google Scholar
• Jain N, Kotla S, Little BB, et al., Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 109(10): 1510–1513. 2012.
   PubMed Web of Science ®Google Scholar
• Kovedsky CP. Updates in hyperkalemia: outcomes and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):41–47.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84(12):934–942.
   PubMed Web of Science ®Google Scholar
• Mahoney BA, Smith WA, Lo DS, et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005; (2): CD003235. doi: 10.1002/14651858.CD003235.pub2.
   PubMed Web of Science ®Google Scholar
• Acker CG, Johnson JP, Palevsky PM, et al. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8):917–924. .
   PubMedGoogle Scholar
• Elliott MJ, Ronksley PE, Clase CM, et al., Management of patients with acute hyperkalemia. CMAJ. 182(15): 1631–1635. 2010. .
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Topaloglu H, Kumar S. Trends in emergency room visits due to hyperkalemia in the United States. Value Health. 2015;18(7):A386.
   Web of Science ®Google Scholar
• Nilsson E, Gasparini A, Ärnlöv J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277–284.
   PubMed Web of Science ®Google Scholar
• Betts KA, Woolley JM, Mu F, et al. The prevalence of hyperkalemia in the United States. CurrMed Res Op. 2018;34(6):971–978.
   PubMed Web of Science ®Google Scholar
• Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int Urol Nephrol. 2000;32(2):177–180.
   PubMedGoogle Scholar
• Lindner G, Burdmann EA, Clase CM, et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: improving Global Outcomes conference. Eur J Emerg Med 2020;27:329–337.
   Google Scholar
• Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014;2:251–257.
   Google Scholar
• Chang AR, Sang Y, Leddy J, et al. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System. Hypertension. 2016;67:1181–1188.
   PubMed Web of Science ®Google Scholar
• Linde C, Qin L, Bakhai A, et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21334 patients in the UK. ESC Heart Fail. 2019;6(2):280–290.
   PubMed Web of Science ®Google Scholar
• Sarwar CM, Papadimitriou L, Pitt B, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68:1575–1589.
   PubMed Web of Science ®Google Scholar
• Latts LM, Reaven NL, Funk SE, et al. Hyperkalemia is prevalent in patients with cardiorenal comorbidities. Poster presented at: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting; 2015 May 16-20; Philadelphia, PA. Available at: https://www.ispor.org/research_pdfs/49/pdffiles/PCV33.pdf.
   Google Scholar
• Ferreira JP, Butler J, Rossignol P, et al., Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 75(22): 2836–2850. 2020.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Pitt B, Reaven N, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213–221.
   PubMed Web of Science ®Google Scholar
• Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(Suppl):S212–20.
   PubMedGoogle Scholar
• Grodzinsky A, Goyal A, Gosch K, et al. Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. Am J Med. 2016;129(8):858–865.
   PubMed Web of Science ®Google Scholar
• Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34(Suppl3):iii2–11.
   PubMedGoogle Scholar
• Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531–538.
   PubMed Web of Science ®Google Scholar
• Savarese G, Xu H, Trevisan M, et al., Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 7(1): 65–76. 2019.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014;7(4):573–579.
   PubMed Web of Science ®Google Scholar
• Desai AS, Liu J, Pfeffer MA, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018;24(5):313–320.
   PubMed Web of Science ®Google Scholar
• Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156–66.
   PubMed Web of Science ®Google Scholar
• Henz S, Maeder MT, Huber S, et al. Influence of drugs and comorbidity on serum potassium in 15,000 consecutive hospital admissions. Nephrol Dial Transplant. 2008;16(12):3 939–3945.
   Google Scholar
• Adelborg K, Nicolaisen SK, Hasvold P, et al. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study. PLoS One. 2019;14(6):e0218739.
   PubMed Web of Science ®Google Scholar
• Jun M, Jardine MJ, Perkovic V, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study. PLoS One. 2019;14(3):e0213192.
   PubMed Web of Science ®Google Scholar
• Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. Arch Intern Med. 1998;158(1):26–32.
   PubMedGoogle Scholar
• Bandak G, Sang YY, Gaspirini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm creatinine measurements (SCREAM) project. J Am Heart Assoc. 2017;6(7):1–13.
   Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. N Engl J Med. 2004;351(6):585–592.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–1184. .
   PubMed Web of Science ®Google Scholar
• Michel A, Martin-Pérez M, Ruigómez A, et al. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail. 2015;17(2):205–213.
   PubMed Web of Science ®Google Scholar
• Hu LJ, Chen YQ, Deng SB, et al. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis. Br J Clin Pharmacol. 2013;75(5):1202–1212.
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054): 747–5. doi: 10.1016/S0140-6736(97)01187-2.
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582–1587.
   PubMed Web of Science ®Google Scholar
• McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100(10):1056–1064. .
   PubMed Web of Science ®Google Scholar
• Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study group. Kinney Int. 2000;58:2084-2092.
   Google Scholar
• Goldberg AI, Dunlay MC, Sweet CS. Sweet CS: safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75(12):793–795.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25(6):1345–1350. .
   PubMed Web of Science ®Google Scholar
• Mimran A, Ruilope L, Kerwin L, et al. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild to moderate hypertension. J Hum Hypertens. 1998;12(3):203–208. .
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
   PubMed Web of Science ®Google Scholar
• Investigators ONTARGET, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Sadjadi SA, McMillan JI, Jaipaul N, et al. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag. 2009;5(3):547–552.
   PubMedGoogle Scholar
• McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Jjv M, Anand IS, et al. PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609–1620.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548. .
   PubMed Web of Science ®Google Scholar
• Abbas S, Ihle P, Harder S, et al. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf. 2015;24(4):406–413. .
   PubMed Web of Science ®Google Scholar
• Hoppe LK, Muhlack DC, Koenig W, et al. Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Cardiovasc Drugs Ther. 2018;32(2):197–212. .
   PubMed Web of Science ®Google Scholar
• McMahon GM, Mendu ML, Gibbons FK, et al. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012;38(11):1834–1842. .
   PubMed Web of Science ®Google Scholar
• El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011;18(3):233–245.
   PubMed Web of Science ®Google Scholar
• Freeman K, Feldman JA, Mitchell P, et al. Effects of presentation and electrocardiogram on time to treatment of hyperkalemia. Acad Emerg Med. 2008;15(3):239–249.
   PubMed Web of Science ®Google Scholar
• Alfonzo AV, Isles C, Geddes C, et al. Potassium disorders - clinical spectrum and emergency management. Resuscitation. 2006;70:10-25.
   Web of Science ®Google Scholar
• Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246–3251.
   PubMed Web of Science ®Google Scholar
• Wang AY. Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrol Dial Transplant. 2019;34(Suppl3):iii36–iii44.
   PubMedGoogle Scholar
• Panchal AR, Bartos JA, Cabañas JG, et al. Adult Basic and Advanced Life Support Writing Group. Part 3: adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(Suppl2):S366–468.
   PubMedGoogle Scholar
• Ballantyne F, Davis LD, Reynolds EW. Cellular basis for reversal of hyperkalemic electrocardiographic changes by sodium. Am J Physiol. 1975;229(4):935–940.
   PubMedGoogle Scholar
• Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: something old, something new. Kidney Int. 2016;89(3):546–554.
   PubMed Web of Science ®Google Scholar
• Ho K. A critically swift response: insulin-stimulated potassium and glucose transport in skeletal muscle. Clin J Am Soc Nephrol. 2011;6(7):1513–1516.
   PubMed Web of Science ®Google Scholar
• Harel Z, Kamel K. Optimal dose and method of administration of intravenous insulin in the management of emergency hyperkalemia: a systematic review. PLoS One. 2016;1–12;11(5):e0154963.
   Web of Science ®Google Scholar
• Bilotta F, Badenes R, Lolli S, et al. Insulin infusion therapy in critical care patients: regular insulin vs short-acting insulin. A prospective, crossover, randomized, multicenter blind study. J Crit Care. 2015;30(437):e1–6.
   Google Scholar
• Long B, Warix JR, Koyfman A. Risks of hypoglycemia with insulin therapy for hyperkalemia. J Emerg Med. 2019;56(4):459–460.
   PubMed Web of Science ®Google Scholar
• LaRue HA, Peksa GD, Shah SC. A comparison of insulin doses for the treatment of hyperkalemia in patients with renal insufficiency. Pharmcotherapy. 2017;37(12):1516–1522.
   PubMed Web of Science ®Google Scholar
• McNicholas BA, Pham MH, Carli K, et al. Treatment of Hyperkalemia With a Low-Dose Insulin Protocol Is Effective and Results in Reduced Hypoglycemia. Kidney Int Rep. 2017;3(2):328–336.
   PubMed Web of Science ®Google Scholar
• Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–1367.
   PubMed Web of Science ®Google Scholar
• Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol mtered-dose inhaler with spacer for hyperkalaemia. How fast? How safe? Chest. 1999;115(3):617–622.
   PubMed Web of Science ®Google Scholar
• Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869–872.
   PubMed Web of Science ®Google Scholar
• Ngugi NN, McLigeyo SO, Kayima JK. Treatment of hyperkalemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East Afr Med J. 1997;74(8):503–509.
   PubMed Web of Science ®Google Scholar
• Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15(5):605–621.
   PubMed Web of Science ®Google Scholar
• Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–1975.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee to Review the Dietary Reference Intakes for Sodium and Potassium; Oria M, Harrison M, Stallings VA, editors. Dietary Reference Intakes for Sodium and Potassium. Washington (DC): National Academies Press (US); 2019 Mar 5. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538102/ doi:10.17226/25353
   Google Scholar
• Lokelma™ (sodium zirconium cyclosilicate) for oral suspension. Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf. Last accessed: 2017 Oct 15.
   Google Scholar
• Veltassa™ (patiromer) for oral suspension. Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205739s016lbl.pdf. Last accessed: 2020 Oct 25.
   Google Scholar
• Kayexalate® (sodium polystyrene sulfonate). Bridgewater, NJ: sanofi-aventis US LLC. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/011287s026lbl.pdf. Last accessed: 2017 Oct 15.
   Google Scholar
• Parks M, Grady D. Sodium Polystyrene Sulfonate for Hyperkalemia. JAMA Intern Med. 2019;179(8):1023.
   Web of Science ®Google Scholar
• Nasir K, Ahmad A. Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. J Ayub Med Coll Abbottabad. 2014;26:455–458.
   PubMedGoogle Scholar
• Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10(12):2136–2142.
   PubMed Web of Science ®Google Scholar
• Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e269-224.
   Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al., AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: the AMETHYST-DN Randomized Clinical Trial. JAMA. 314(2): 151–161. 2015. .
   PubMed Web of Science ®Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–828.
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al., OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 372(3): 211–221. 2015.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–1550. .
   PubMed Web of Science ®Google Scholar
• Rafique Z, Liu M, Staggers KA, et al. Patiromer for Treatment of Hyperkalemia in the Emergency Department: a Pilot Study. Acad Emerg Med. 2020;27(1):54–60. .
   PubMed Web of Science ®Google Scholar
• Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014;9(12):e114686.
   PubMed Web of Science ®Google Scholar
• Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404–411.
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222–231.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Rasmussen HS, Lavin P, et al., Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. JAMA. 312(21): 2223–2233. 2014. .
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. N Engl J Med. 2015;372(16):1577–1578.
   PubMed Web of Science ®Google Scholar
• Spinowitz BS, Fishbane S, Pergola PE, et al. ZS-005 Study Investigators. Sodium zirconium cyclosilicate in individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798–809.
   PubMed Web of Science ®Google Scholar
• Peacock WF, Rafique Z, Vishnevskiy K, et al. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: a Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE). Acad Emerg Med. 2020;27(6):475–486.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. J Am Soc Nephrol. 2019;30(9):1723–1733.
   PubMed Web of Science ®Google Scholar
• Horne L, Ashfaq A, MacLachlan S, et al. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol. 2019;20(1):85.
   PubMed Web of Science ®Google Scholar
• Cooper LB, Hammill BG, Peterson ED, et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA. 2015;314(18):1973–1975.
   PubMed Web of Science ®Google Scholar
• Batterink J, Cessford TA, Taylor RAI. Pharmacological interventions for the acute management of hyperkalaemia in adults. Cochrane Database Syst Rev. 2015;10:CD010344.
   Google Scholar